Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 3
1982 1
1983 1
1986 1
1988 3
1989 1
1990 2
1991 2
1992 2
1993 2
1994 1
1995 3
1996 1
1997 6
1998 2
1999 5
2000 3
2001 2
2002 3
2003 2
2004 4
2005 9
2006 5
2007 9
2008 6
2009 9
2010 7
2011 6
2012 10
2013 4
2014 17
2015 16
2016 15
2017 20
2018 17
2019 13
2020 17
2021 14
2022 14
2023 13
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

240 results

Results by year

Filters applied: . Clear all
Page 1
Myelofibrosis.
Passamonti F, Mora B. Passamonti F, et al. Blood. 2023 Apr 20;141(16):1954-1970. doi: 10.1182/blood.2022017423. Blood. 2023. PMID: 36416738 Free PMC article. Review.
Currently available clinical-based and integrated clinical/molecular-based scoring systems predict the survival of patients with MF and are applied for conventional treatment decision-making, indication to stem cell transplant (SCT) and allocation in clinical trials. ...SC …
Currently available clinical-based and integrated clinical/molecular-based scoring systems predict the survival of patients with MF a …
Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update.
Jain AG, Zhang L, Bennett JM, Komrokji R. Jain AG, et al. Ann Lab Med. 2022 May 1;42(3):299-305. doi: 10.3343/alm.2022.42.3.299. Ann Lab Med. 2022. PMID: 34907099 Free PMC article. Review.
Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international prognostic scoring system (IPSS-R). ...In this review, we discuss the available literature about the presentation and prognosis of patient …
Treatment strategies for patients with MDS heavily rely on prognostic scoring systems, such as the revised international prognosti …
Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA, Chifotides HT, Bose P, Masarova L, Verstovsek S. Shahin OA, et al. Acta Haematol. 2021;144(5):484-499. doi: 10.1159/000512929. Epub 2021 Apr 21. Acta Haematol. 2021. PMID: 33882481 Free PMC article. Review.
MPN-AP and MPN-BP are characterized by 10-19% and 20% blasts, respectively. MPN-AP/BP portend a dismal prognosis with no established conventional treatment. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the sole modality associated with long-term surviv …
MPN-AP and MPN-BP are characterized by 10-19% and 20% blasts, respectively. MPN-AP/BP portend a dismal prognosis with no established …
Management of myelofibrosis after ruxolitinib failure.
Harrison CN, Schaap N, Mesa RA. Harrison CN, et al. Ann Hematol. 2020 Jun;99(6):1177-1191. doi: 10.1007/s00277-020-04002-9. Epub 2020 Mar 20. Ann Hematol. 2020. PMID: 32198525 Free PMC article. Review.
Transplant is the only curative option for myelofibrosis, but high rates of morbidity and mortality limit eligibility. Several prognostic models have been developed to facilitate treatment decisions. ...
Transplant is the only curative option for myelofibrosis, but high rates of morbidity and mortality limit eligibility. Several prognostic …
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Guglielmelli P, Lasho TL, Rotunno G, Mudireddy M, Mannarelli C, Nicolosi M, Pacilli A, Pardanani A, Rumi E, Rosti V, Hanson CA, Mannelli F, Ketterling RP, Gangat N, Rambaldi A, Passamonti F, Barosi G, Barbui T, Cazzola M, Vannucchi AM, Tefferi A. Guglielmelli P, et al. J Clin Oncol. 2018 Feb 1;36(4):310-318. doi: 10.1200/JCO.2017.76.4886. Epub 2017 Dec 9. J Clin Oncol. 2018. PMID: 29226763 Free article.
Purpose To develop a prognostic system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cytogenetic, and mutation data. ...A Cox multivariable model was used to select from among a list of 22 variables those that were predictiv …
Purpose To develop a prognostic system for transplantation-age patients with primary myelofibrosis (PMF) that integrates clinical, cy …
Treating early-stage myelofibrosis.
Palandri F, Sabattini E, Maffioli M. Palandri F, et al. Ann Hematol. 2019 Feb;98(2):241-253. doi: 10.1007/s00277-018-3526-z. Epub 2018 Oct 20. Ann Hematol. 2019. PMID: 30343328 Review.
Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm associated with bone marrow fibrosis, splenomegaly, a high symptom burden, and poor prognosis. Treatment is based on a risk-adapted approach, with treatment guidelines generally recommendi …
Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm associated with bone marrow fibrosis, splenomegaly, a h …
Role of IL8 in myeloid malignancies.
Ramachandra N, Gupta M, Schwartz L, Todorova T, Shastri A, Will B, Steidl U, Verma A. Ramachandra N, et al. Leuk Lymphoma. 2023 Nov-Dec;64(11):1742-1751. doi: 10.1080/10428194.2023.2232492. Epub 2023 Jul 19. Leuk Lymphoma. 2023. PMID: 37467070 Review.
IL8/CXCR1/2 overexpression has been associated with poorer prognosis in MDS and AML and increased bone marrow fibrosis in Myelofibrosis. ...
IL8/CXCR1/2 overexpression has been associated with poorer prognosis in MDS and AML and increased bone marrow fibrosis in Myelofibros …
Management of Myelofibrosis-Related Cytopenias.
Bose P, Verstovsek S. Bose P, et al. Curr Hematol Malig Rep. 2018 Jun;13(3):164-172. doi: 10.1007/s11899-018-0447-9. Curr Hematol Malig Rep. 2018. PMID: 29796726 Review.
Idiopathic myelofibrosis.
Barosi G, Hoffman R. Barosi G, et al. Semin Hematol. 2005 Oct;42(4):248-58. doi: 10.1053/j.seminhematol.2005.05.018. Semin Hematol. 2005. PMID: 16210038 Review.
Using such parameters as hemoglobin level, white blood cell count, and number of blasts in the peripheral blood, prognostic scores can be developed by which to base therapeutic decisions. ...
Using such parameters as hemoglobin level, white blood cell count, and number of blasts in the peripheral blood, prognostic scores ca …
Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies.
Zahr AA, Salama ME, Carreau N, Tremblay D, Verstovsek S, Mesa R, Hoffman R, Mascarenhas J. Zahr AA, et al. Haematologica. 2016 Jun;101(6):660-71. doi: 10.3324/haematol.2015.141283. Haematologica. 2016. PMID: 27252511 Free PMC article. Review.
A number of studies indicate that bone marrow fibrosis is an adverse prognostic variable in myeloproliferative neoplasms. However, modern myelofibrosis prognostication systems utilized in risk-adapted treatment approaches do not include bone marrow fibrosis as a …
A number of studies indicate that bone marrow fibrosis is an adverse prognostic variable in myeloproliferative neoplasms. However, mo …
240 results